Skip to main content
OpenTrials

Clinical trial condition

Relapsed or Refractory Multiple Myeloma

Explore clinical trials studying Relapsed or Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

44 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Relapsed or Refractory Multiple Myeloma trial results

Active, not recruiting

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • Jewish General Hospital Montreal, Quebec, Canada
  • Seoul National University Hospital Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
View all 15 locations
View Trial Details
Active, not recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

NCT04684108

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations
  • The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China
  • Affiliated Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hostipal Beijing, Beijing Municipality, China
  • Shenzhen Second People's Hospital Shenzhen, Guangzhou, China
View all 14 locations
View Trial Details
Active, not recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
  • MemorialCare Long Beach Medical Center Long Beach, California, United States
View all 211 locations
View Trial Details
Completed

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04939142

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • The First Affiliated Hospital OF USTC Hefei, Anhui, China
  • The First Affiliated Hospital of Wannan Medical College Wuhu, Anhui, China
  • Beijing Chao-Yang Hospital Beijing, Beijing Municipality, China
View all 33 locations
View Trial Details
Completed

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Rocky Mountain Cancer Centers Denver Midtown Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Affiliated Oncologists, LLC Chicago Ridge, Illinois, United States
View all 46 locations
View Trial Details
Completed

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

NCT06163040

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Chang Gung Memorial Hospital- Chiayi Chiayi City, Chiayi, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • National Taiwan University Hospital Taipei, Taiwan
  • China Medical University Hospital Taoyuan City, Taiwan
View Trial Details
Completed

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

NCT06055075

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Alexandra Hospital Woolloongabba Woolloongabba, Queensland, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Hamilton Health Sciences Hamilton, Ontario, Canada
  • Istituto Clinico Humanitas Rozzano, Lombardy, Italy
View Trial Details
Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • James R. Berenson, MD, Inc. West Hollywood, California, United States
  • Northside Hospital Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinical Rochester Rochester, Minnesota, United States
View Trial Details

Related conditions